Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

Open Access 01-10-2019 | Diabetic Retinopathy | Retinal Disorders

Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage

Authors: Reinhard Angermann, Teresa Rauchegger, Yvonne Nowosielski, Marina Casazza, Angelika Bilgeri, Hanno Ulmer, Claus Zehetner

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2019

Abstract

Purpose

To analyze and compare loss to follow-up (LTFU) rates between patients with diabetic retinopathy (DR) and those with neovascular age-related macular degeneration (nAMD) in patients, receiving treatment with anti-vascular endothelial growth factor (VEGF), under universal health coverage.

Methods

We retrospectively analyzed the relevant data of 1264 patients receiving anti-VEGF therapy, in this cohort study. The observation period ranged from September 01, 2015 to December 31, 2018. Intervals between each procedure and the subsequent follow-up examination were measured. Demographic data, visual acuity (VA), the type of transport for treatment access, and distance between the residence and clinic were evaluated as risk factors for LTFU.

Results

We collected data for 841 patients with nAMD (age, 81.0 (± 8.1 years)) and 423 patients with DR (age, 67.7 (± 12.1 years)). The rate of LTFU, for at least 6 months, was 28.8% and 2.9% for patients with DR and nAMD, respectively (p < 0.001). In the DR group, 18.9% patients were lost to follow-up exceeding > 12 months. Multivariate regression analysis showed that advanced age, lack of mobility, and need for assisted transport, poor final VA despite treatment, and decrease in vision during the observational period were independent risk factors for LTFU exceeding 12 months (p < 0.05).

Conclusions

We found a high long-term LTFU rate for patients with DR, despite treatment under universal health coverage. Considering the risk of disease progression, particularly in patients with chronic DR, strategies for better compliance and adherence to therapy should be considered for optimized patient care.

Antonetti DA, Klein R, Gardner TW (2012) Diabetic retinopathy. N Engl J Med 366:1227–1239. https://doi.org/10.1056/NEJMra1005073 CrossRefPubMed

Deshpande AD, Harris-Hayes M, Schootman M (2008) Epidemiology of diabetes and diabetes-related complications. Phys Ther 88:1254–1264. https://doi.org/10.2522/ptj.20080020 CrossRefPubMedPubMedCentral

Egan C, Zhu H, Lee A et al (2017) The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema. Br J Ophthalmol 101:75–80. https://doi.org/10.1136/bjophthalmol-2016-309313 CrossRefPubMed

Obeid A, Gao X, Ali FS et al (2018) Loss to follow-up among patients with neovascular age-related macular degeneration who received intravitreal anti–vascular endothelial growth factor injections. JAMA Ophthalmol 136:1251–1259. https://doi.org/10.1001/jamaophthalmol.2018.3578 CrossRefPubMedPubMedCentral

Obeid A, Gao X, Ali FS et al (2018) Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections. Ophthalmology 125:1386–1392. https://doi.org/10.1016/j.ophtha.2018.02.034 CrossRefPubMed

Elam AR, Lee PP (2013) High-risk populations for vision loss and eye care underutilization: a review of the literature and ideas on moving forward. Surv Ophthalmol 58:348–358. https://doi.org/10.1016/j.survophthal.2012.07.005 CrossRefPubMed

Li Y-J, Xirasagar S, Pumkam C et al (2013) Vision insurance, eye care visits, and vision impairment among working-age adults in the United States. JAMA Ophthalmol 131:499–506CrossRef

Paksin-Hall A, Dent ML, Dong F, Ablah E (2013) Factors contributing to diabetes patients not receiving annual dilated eye examinations. Ophthalmic Epidemiol 20:281–287. https://doi.org/10.3109/09286586.2013.789531 CrossRefPubMed

Nelson KM, Chapko MK, Reiber G, Boyko EJ (2005) The association between health insurance coverage and diabetes care; data from the 2000 behavioral risk factor surveillance system. Health Serv Res 40:361–372. https://doi.org/10.1111/j.1475-6773.2005.00361.x CrossRefPubMedPubMedCentral

10.

Oladele CRW, Barnett E (2006) Racial/ethnic and social class differences in preventive care practices among persons with diabetes. BMC Public Health 6:259. https://doi.org/10.1186/1471-2458-6-259 CrossRefPubMedPubMedCentral

11.

World Health Organisation (2016). International statistical classification of diseases and related health problems 10th revision (ICD-10). Visual impairment including blindness (binocular or monocular). https://icd.who.int/browse10/2016/en#/H53-H54. Accessed 14 Mar 2019

12.

Sivaprasad S, Prevost AT, Vasconcelos JC et al (2017) Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet 389:2193–2203. https://doi.org/10.1016/S0140-6736(17)31193-5 CrossRefPubMed

13.

Gross JG, Glassman AR, Jampol LM et al (2015) Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137–2146. https://doi.org/10.1001/jama.2015.15217 CrossRefPubMedPubMedCentral

14.

Obeid A, Su D, Patel SN et al (2018) Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 126:407–413. https://doi.org/10.1016/j.ophtha.2018.07.027 CrossRefPubMed

15.

Cramer JA, Benedict Á, Muszbek N et al (2008) The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. Int J Clin Pract 62:76–87. https://doi.org/10.1111/j.1742-1241.2007.01630.x CrossRefPubMedPubMedCentral

16.

Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26:331–342CrossRef

17.

Piccirillo JF, Vlahiotis A, Barrett LB et al (2008) The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 67:124–132. https://doi.org/10.1016/j.critrevonc.2008.01.013 CrossRefPubMedPubMedCentral

18.

Campbell J, Dugel PU, Cole A et al (2015) Comorbidity and healthcare visit burden in elderly diabetic macular edema patients. Invest Ophthalmol Vis Sci 56:2145–2145

19.

Weiss M, Sim DA, Herold T et al (2018) Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina (Philadelphia, Pa) 38:2293–2300. https://doi.org/10.1097/IAE.0000000000001892 CrossRef

20.

Wang X-X, Lin W-Q, Chen X-J et al (2017) Multimorbidity associated with functional independence among community-dwelling older people: a cross-sectional study in southern China. Health Qual Life Outcomes 15:73. https://doi.org/10.1186/s12955-017-0635-7 CrossRefPubMedPubMedCentral

21.

Boulanger-Scemama E, Querques G, About F et al (2015) Ranibizumab for exudative age-related macular degeneration: a five year study of adherence to follow-up in a real-life setting. J Fr Ophtalmol 38:620–627. https://doi.org/10.1016/j.jfo.2014.11.015 CrossRefPubMed

22.

Droege KM, Muether PS, Hermann MM et al (2013) Adherence to ranibizumab treatment for neovascular age-related macular degeneration in real life. Graefes Arch Clin Exp Ophthalmol 251:1281–1284. https://doi.org/10.1007/s00417-012-2177-3 CrossRefPubMed

23.

Saadine JB, Fong DS, Yao J (2008) Factors associated with follow-up eye examinations among persons with diabetes. Retina (Philadelphia, Pa) 28:195–200. https://doi.org/10.1097/IAE.0b013e318115169a CrossRef

24.

Wong TY, Mwamburi M, Klein R et al (2009) Rates of progression in diabetic retinopathy during different time periods. Diabetes Care 32:2307–2313. https://doi.org/10.2337/dc09-0615 CrossRefPubMedPubMedCentral

25.

Harris Nwanyanwu K, Talwar N, Gardner TW et al (2013) Predicting development of proliferative diabetic retinopathy. Diabetes Care 36:1562–1568. https://doi.org/10.2337/dc12-0790 CrossRefPubMedPubMedCentral

26.

Downer SR, Meara JG, Da Costa AC (2005) Use of SMS text messaging to improve outpatient attendance. Med J Aust 183:366–368CrossRef

27.

Dervan E, Lillis D, Flynn L et al (2008) Factors that influence the patient uptake of diabetic retinopathy screening. Ir J Med Sci 177:303. https://doi.org/10.1007/s11845-008-0192-5 CrossRefPubMed

28.

Lian J, McGhee SM, Gangwani RA et al (2018) Awareness of diabetic retinopathy and its association with attendance for systematic screening at the public primary care setting: a cross-sectional study in Hong Kong. BMJ Open 8:e019989. https://doi.org/10.1136/bmjopen-2017-019989 CrossRefPubMedPubMedCentral

29.

Trento M, Bajardi M, Borgo E et al (2002) Perceptions of diabetic retinopathy and screening procedures among diabetic people. Diabet Med 19:810–813CrossRef

Title: Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage
Authors: Reinhard Angermann
Teresa Rauchegger
Yvonne Nowosielski
Marina Casazza
Angelika Bilgeri
Hanno Ulmer
Claus Zehetner
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Keywords: Diabetic Retinopathy
Macular Degeneration
Diabetic Retinopathy
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2019
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-019-04414-y

ACC 2024 Congress

Springer Medicine

Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health coverage

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2019

Phototoxicity of environmental radiations in human lens: revisiting the pathogenesis of UV-induced cataract

Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab

Prophylactic intracameral cefazolin and postoperative topical moxifloxacin after cataract surgery: endophthalmitis risk reduction and safety results in a 16-year study

Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis

Efficacy of intensity-modulated radiation therapy for optic nerve sheath meningioma

Comparison of conjunctival vascularity changes using optical coherence tomography angiography after trabeculectomy and phacotrabeculectomy